Zocchi Jacopo, Giugliano Gioacchino, Mossinelli Chiara, Mariani Cecilia, Pietrobon Giacomo, Bandi Francesco, Malpede Stefano, Grosso Enrica, Manzoni Marco Federico, De Fiori Elvio, Mauri Giovanni, Rubino Manila, Tagliabue Marta, Ansarin Mohssen
Department of Otorhinolaryngology and Head and Neck Surgery, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy.
Department of Otorhinolaryngology, Bassini Hospital, ASST Nord Milano, 20092 Cinisello Balsamo, Italy.
Biomedicines. 2024 Sep 25;12(10):2177. doi: 10.3390/biomedicines12102177.
Surgery is still the main line of treatment for papillary thyroid cancer (PTC) with a current trend for de-intensified treatment based on an excellent prognosis. The role of a routine prophylactic central neck dissection (PCND) is still debated as its impact on oncologic outcomes has never been cleared by a randomized clinical trial. In this study, we aimed to report our long-standing experience in PCND and its potential contemporary role in the treatment of PTC.
A retrospective institutional review was performed on all patients who underwent operation for PTC including PCND between 1998 and 2021. The primary outcomes were the rate of central lymph node metastases (CLNMs), cancer recurrence and incidence of complications. Survivals were analyzed using the Kaplan-Meier estimator and Cox proportional hazard models.
A total of 657 patients were included in this study with a median follow-up of 78 months (48-114 months). Two hundred and one patients presented occult CLNMs (30.6%). The presence of a pathological node represented the unique reason for a completion thyroidectomy and I therapy in 12.5% of the population. Age lower than 55 years, microscopic or macroscopic extra-thyroid extension (ETE) and multifocality were independent factors predicting CLNMs. The rate of recurrence in the whole population was 2.7% (18 patients). Five-year and ten-year disease-free survival (DFS) was 96.5% (94.7-97.7) and 93.3% (90.3-95.5), respectively. Two patients relapsed in the central neck compartment (0.3%). Age (>55 years), pathological staging (pT) and extranodal extension (ENE) were independent factors associated with a worse DFS. The rate of temporary and permanent vocal fold palsy was 12.8% and 1.8%, respectively, and did not depend on the type of surgical procedure performed. Hypoparathyroidism was temporary in 42.2% and permanent in 11.9% of the patients. A sub-analysis upon cT1b-T2 patients treated primarily with thyroid lobectomy and ipsilateral PCND demonstrated a 2.6% rate of permanent hypoparathyroidism.
PCND allows for a high disease-free survival and a proper selection of patients needing adjuvant treatment, in particular, those treated with a unilateral procedure. On the other hand, bilateral approach is burdened by a not-neglectable rate of permanent hypoparathyroidism.
手术仍是甲状腺乳头状癌(PTC)的主要治疗方法,鉴于其预后良好,目前有治疗强度降低的趋势。常规预防性中央区颈淋巴结清扫术(PCND)的作用仍存在争议,因为其对肿瘤学结局的影响从未通过随机临床试验得以明确。在本研究中,我们旨在报告我们在PCND方面的长期经验及其在PTC治疗中的当代潜在作用。
对1998年至2021年间接受包括PCND在内的PTC手术的所有患者进行回顾性机构审查。主要结局为中央区淋巴结转移(CLNMs)率、癌症复发率和并发症发生率。使用Kaplan-Meier估计器和Cox比例风险模型分析生存率。
本研究共纳入657例患者,中位随访时间为78个月(48 - 114个月)。201例患者出现隐匿性CLNMs(30.6%)。病理淋巴结的存在是12.5%的患者行甲状腺全切术和碘治疗的唯一原因。年龄低于55岁、显微镜下或肉眼可见的甲状腺外侵犯(ETE)和多灶性是预测CLNMs的独立因素。总体复发率为2.7%(18例患者)。5年和10年无病生存率(DFS)分别为96.5%(94.7 - 97.7)和93.3%(90.3 - 95.5)。2例患者在中央区颈部复发(0.3%)。年龄(>55岁)、病理分期(pT)和结外侵犯(ENE)是与较差DFS相关的独立因素。暂时性和永久性声带麻痹发生率分别为12.8%和1.8%,且与所施行的手术类型无关。甲状旁腺功能减退在42.2%的患者中为暂时性,在11.9%的患者中为永久性。对主要接受甲状腺叶切除术和同侧PCND治疗的cT1b - T2患者进行的亚组分析显示,永久性甲状旁腺功能减退发生率为2.6%。
PCND可实现较高的无病生存率,并能正确选择需要辅助治疗的患者,特别是那些接受单侧手术的患者。另一方面,双侧手术方式存在不可忽视的永久性甲状旁腺功能减退发生率。